Refine by
Colon Cancer Articles & Analysis
61 news found
Colorectal cancer affects the colon or rectum and is on the rise among young adults. ...
“Vincere Cancer Center is committed to providing the best and latest cancer care. ...
SEngine utilizes breakthrough science from cancer genomics, robotics, and proprietary algorithms. SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. ...
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. ...
We believe Check-Cap has the potential to reach those who are deterred by colonoscopy and to help improve colon cancer screening through a patient-friendly solution without the need of bowel cleaning, sedation, and fasting." ...
Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...
The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer. Highlights Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions Four presentations describe ...
(Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022. ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast ...
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. ...
The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer at the University of Washington, ordered the PARIS® Test. The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
“We know that colorectal cancer is the deadliest cancer for young Australians. We also know that there has been a nearly 190% increase in colorectal cancer cases in adolescents and young people in Australia over the last 30 years. ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test ...
Proximie has teamed up with Vodafone to pilot the role of 5G in increasing the connectivity and performance of remote assistance and training in cancer care. Trial with the assistance of 5G in using Proxime to ‘scrub in’ clinicians is taking place at University Hospital of Wales and University Hospital Llandough. Trial will be used in the diagnosis and treatment of ...
US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery. The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures. ...
Pittsburgh, PA – (April 30, 2021) – The Bladder Health Foundation announces the rollout of the first on-line patient registry for pelvic radiation cancer survivors. The online registry is located at www.radiationcystitis.com The Bladder Health Foundation, with support from Lipella Pharmaceuticals Inc., is promoting the awareness of a serious bladder health ...
SEngine’s CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Cancer-derived cells grown in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics. For ...